Radiopharmaceutical startup Actithera has secured $75.5 million in Series A funding to propel clinical development of a novel treatment targeting fibroblast activation protein (FAP) expressed in tumors. Founded by veteran Andreas Goutopoulos, the company focuses on delivering radioligand therapies that bind tightly to tumors, enhancing therapeutic precision and effectiveness. The funding round was co-led by M Ventures and Hadean Ventures, with participation from Sofinnova Partners, 4BIO Capital, and others. Despite being a single-person operation during the raise, Actithera successfully convinced investors by leveraging strong scientific data and commitments from key opinion leaders. The funding will support Actithera’s entry into clinical trials and build a leadership team for further development. Radiopharmaceuticals have attracted increasing interest, with successes like Novartis’ Pluvicto showcasing their market potential. Actithera’s approach aims to dismantle tumor-supporting fibroblasts, creating a cross-fire effect that kills adjacent cancer cells, potentially improving immune and therapeutic access to tumors.